Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 81.00 23,209 08:00:16
Bid Price Offer Price High Price Low Price Open Price
80.00 82.00 81.00 81.00 81.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.07 -13.86 -35.90 26
Last Trade Time Trade Type Trade Size Trade Price Currency
12:34:08 O 12,269 81.50 GBX

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Investors    Reneuron Takeover Rumours

Reneuron (RENE) Discussions and Chat

Reneuron (RENE) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

Reneuron Daily Update: Reneuron Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 81p.
Reneuron Group Plc has a 4 week average price of 74.20p and a 12 week average price of 74.20p.
The 1 year high share price is 178.50p while the 1 year low share price is currently 73p.
There are currently 31,876,324 shares in issue and the average daily traded volume is 181,313 shares. The market capitalisation of Reneuron Group Plc is £25,819,822.44.
onceaday: I wouldn't disagree with your figures. The only points I would make are (i) I remember reading in the placing document that circa 4M is needed for legacy funding (presumably orderly shutdown of the phase 2b in stroke) and (ii) requirements are less predictable the further out we look. For example, I don"t believe I saw any mention of hRPC partnering in the offer documentation although this was mentioned in relation to exosomes. If the RP ph2a extension study yields acceptable results then RENE may decide to finance the ph3 themselves. This was suggested by Edison. It's such a niche market that they would only require a small selling operation. Financing an hRPC ph3 trial might require further cash unless it comes in from one or more exosome deals. If funding was required, I would expect the fund raise to be on the back of good news and an elevated share price, however. Incidently, I see that Codiak (exosomes) IPO"d and the shares went up 30%.
timbo003: >>>az4hr Sorry, I missed that, so I will try to answer here: If a company is going to issue EIS/VCT qualifying shares it will generally (but not always) have obtained advanced approval from HMRC and your broker should know this. So for example, if you look at the book building announcement yesterday (hit control f to search EIS) you will see that some of the shares qualified for EIS It is not unusual for a company to issue both EIS qualifying and non-qualifying shares in the same fund raising round, this is because EIS cash can only be spent of certain activities (growth capital), it cannot be used for activities such as acquisitions, so if a fund raise is for the purposes of an acquisition and to invest in organic growth, it will not be all EIS qualifying. If a placing opportunity does come along, always ask the broker to confirm if any of the shares qualify for EIS and always stipulate that you only wish to be issued with EIS shares. I would recommend that you check with the broker on a one or two monthly basis to see how the process of obtaining your (necessary) EIS3 certificates is coming along. Obtaining the certificates is a clunky process, it can take a while and can get held up for all sorts of reasons, but if you have someone chase it up on a regular basis, you still generally receive the EIS3 certificate within 3 – 9 months. I would say my success rate for obtaining EIS3 certificates is around 90%. You need the EIS3 certificate to make a claim to HMRC for an income tax refund, without an EIS3 certificate you will definitely not get a refund
xow98: Placing RNS ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics , announces its intention to raise gross proceeds of up to GBP13.9 million by means of a placing to institutional and other investors (the "Placing") and a direct subscription with the Company to raise gross proceeds of up to GBP1.1 million (the "Subscription"), in each case at a price of 70 pence per share ("Issue Price"). The net proceeds of the Placing and Subscription will allow the Group, inter alia, to deliver extended clinical data from its ongoing retinitis pigmentosa (RP) Phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals, as detailed below more fully.
onceaday: They have reduced their cash burn by 40% as a result of stopping the CTX trial. Further financing will be needed but they can afford to wait for some good clinical news which will inflate the share price. Most pharmas raise.funds after a material event.
onceaday: They are hard to value because of a dependency on the RP trial and exosome research results that are not yet known. From a share price perspective, hard data on either the RP trial or their internal research programs should move the price upwards. I can only see circa £5 being reached if they announce a significant partnering deal. Taking the ex-US jCyte deal and doubling it to take into account US rights would give $500M. That's well in excess of 10x RENE's market cap. How much is the company worth without a deal? I would imagine that the breakup value is at least the current market cap given their IP portfolio and proprietary technology.
onceaday: The next few months could bring newsflow that may have a significant effect on the share price. It's clear that the phase 2a extension study in RP is underway and if early results are clinically significant then this may be deemed "material" for market reporting purposes. Rene.are also due to report on exosome collaborations "late this year and into next" there could news on CTX partnering outside of China as well as progress by Fosun. The share has drifted down from a high of £3 last year to sub £1 today. Any significant news will command a 30% premium for sure!
supernumerary: I still think rene's CTX stem cells for Huntingtons have value. Results are only in vitro, but nonetheless striking: Others are still trying and failing: all these neurodegenerative diseases seem to be very hard to treat, as you might expect:
onceaday: If you read into the detail of yhe results, you will find it was a triple arm trial - they used a sham (no dose), low dose and high dose arm. Only the high dose arm showed meaningfull efficacy andonly a sub population showed comparable efficacy to RENE's ph2a results.. RENE will treat a further 9 patients at double dose in the ph2a extension trial. The fact that jCute had good results with the same type of hRPC cell validates RENEs work so far amd adds value. I think there will be a number of large pharmas keeping a very close eye (excuse the pun) on the extension trial. It's open label,unlike the jCyte ph2b, so they can announce tesults as they go. Biotech investment is all about timing - it can take years (decades) for value inflection - it could be that RENE's time has finally arrived.
supernumerary: They started some action with the exosomes back at the beginning of 2019: but it seems to have gone nowhere. No use having assets sitting on the shelf gathering dust - if they can't be used they should be sold for whatever they can get, with a payback on future royalties.
s1zematters: supernumerary The previous data has built up a certain amount of expectation. The company recently talked about NHS treatment in a presentation pushed in a you-tube video pumped on this very thread! If the share price yesterday had an element already built in of expectation of widespread future uptake (including nhs) then today's new data questions that somewhat. That was my point!. Shares look forward in this sector by many years, some of the exuberance of the future has been depressed by that data. Moreover, future commercial returns have naturally also been questioned today by some. Temporarily ? Maybe, maybe not! I am not claiming that the treatment in this state would be offered to the NHS as you alluded, that's not only ridiculous, but the genuine "straw man" argument suggesting i was . It's a question mark of expectation of widespread future usage that in part explains the share price collapse today. On one hand You suggest we ignore the steep fall in improvement after 9 months and on the other you assure us that Fosun are happy with the data? It takes a certain sort of narcissistic tendency in owns own investment choices , or maybe just outright reckless abandonment if you choose to discount data you don't like and invent approval from others that you have no way of validating.. Kingpin. That is a very nice share price ride, well done! However,please understand me, i was asked what reason/s do i see the share price falling. My posts have generally been about the impact of that data on the share price going forward until the next data rather than predicting the success or failure long term of the treatment!
Reneuron share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201202 13:00:19